Chemistry Reference
In-Depth Information
57. Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M., and Fedorak, R.
N.,
Lactobacillus
species prevents colitis in interleukin 10 gene-deficient mice,
Gastroenterology
116(5), 1107-14, 1999.
58. Carroll, I. M., Andrus, J. M., Bruno-Barcena, J. M., Klaenhammer, T. R., Hassan, H. M.,
and Threadgill, D. S., Anti-inflammatory properties of
Lactobacillus gasseri
express-
ing manganese superoxide dismutase using the interleukin 10-deficient mouse model of
colitis,
Am J Physiol Gastrointest Liver Physiol
293(4), G729-38, 2007.
59. Frossard, C. P., Steidler, L., and Eigenmann, P. A., Oral administration of an IL-10-
secreting
Lactococcus lactis
strain prevents food-induced IgE sensitization,
J Allergy
Clin Immunol
119(4), 952-59, 2007.
60. Huibregtse, I. L., Snoeck, V., de Creus, A., Braat, H., De Jong, E. C., Van Deventer, S.
J., and Rottiers, P., Induction of ovalbumin-specific tolerance by oral administration of
Lactococcus lactis
secreting ovalbumin,
Gastroenterology
133(2), 517-28, 2007.
61. Hedin, C., Whelan, K., and Lindsay, J. O., Evidence for the use of probiotics and prebiotics
in inflammatory bowel disease: A review of clinical trials,
Proc Nutr Soc
66(3), 307-15,
2007.
62. Gionchetti, P., Rizzello, F., Morselli, C., Poggioli, G., Tambasco, R., Calabrese, C.,
Brigidi, P., Vitali, B., Straforini, G., and Campieri, M., High-dose probiotics for the
treatment of active pouchitis,
Dis Colon Rectum
50(12), 2075-82; discussion 2082-
84, 2007.
63. Kruis, W., Schutz, E., Fric, P., Fixa, B., Judmaier, G., and Stolte, M., Double-blind com-
parison of an oral
Escherichia coli
preparation and mesalazine in maintaining remission
of ulcerative colitis,
Aliment Pharmacol Ther
11 (5), 853-58, 1997.
64. Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., Kamm, M.,
Weismueller, J., Beglinger, C., and Stolte, M., Maintaining remission of ulcerative
colitis with the probiotic
Escherichia coli
Nissle 1917 is as effective as with standard
mesalazine,
BMJ
53(11), 1617-23, 2004.
65. Rembacken, B. J., Snelling, A. M., Hawkey, P. M., Chalmers, D. M., and Axon, A. T.,
Non-pathogenic
Escherichia coli
versus mesalazine for the treatment of ulcerative coli-
tis: A randomised trial,
Lancet
354(9179), 635-39, 1999.
66. Pena, J. A., Rogers, A. B., Ge, Z., Ng, V., Li, S. Y., Fox, J. G., and Versalovic, J., Probiotic
Lactobacillus
spp. diminish
Helicobacter hepaticus
-induced inflammatory bowel dis-
ease in interleukin-10-deficient mice,
Infect Immun
73(2), 912-20, 2005.
67. Dieleman, L., Goerres, M., Arends, A., Sprengers, D., Torrice, C., Hoentjen, F., Grenther,
W., and Sartor, R.,
Lactobacillus
GG prevents recurrence of colitis in HLA-B27 trans-
genic rats after antibiotic treatment,
BMJ
52(3), 370-76, 2003.
68. Lim, C. C., Ferguson, L. R., and Tannock, G. W., Dietary fibres as “prebiotics”:
Implications for colorectal cancer,
Mol Nutr Food Res
49(6), 609-19, 2005.
69. Cummings, J. H., Antoine, J. M., Azpiroz, F., Bourdet-Sicard, R., Brandtzaeg, P., Calder,
P. C., Gibson, G. R., Guarner, F., Isolauri, E., Pannemans, D., Shortt, C., Tuijtelaars,
S., and Watzl, B., PASSCLAIM—Gut health and immunity,
Eur J Nutr
43(Suppl 2),
II118-II173, 2004.
70. Guarner, F., Prebiotics in inflammatory bowel diseases,
Br J Nutr
98(Suppl 1), S85-89,
2007.
71. Roberfroid, M. B., Prebiotics and synbiotics: Concepts and nutritional properties,
Br J
Nutr
80(4), S197-202, 1998.
72. Sartor, R. B., Therapeutic manipulation of the enteric microflora in inflammatory bowel
diseases: Antibiotics, probiotics, and prebiotics,
Gastroenterology
126(6), 1620-33,
2004.
